JP5866601B2 - 医薬組成物の製造方法 - Google Patents

医薬組成物の製造方法 Download PDF

Info

Publication number
JP5866601B2
JP5866601B2 JP2011514618A JP2011514618A JP5866601B2 JP 5866601 B2 JP5866601 B2 JP 5866601B2 JP 2011514618 A JP2011514618 A JP 2011514618A JP 2011514618 A JP2011514618 A JP 2011514618A JP 5866601 B2 JP5866601 B2 JP 5866601B2
Authority
JP
Japan
Prior art keywords
cells
tsg
msc
protein
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011514618A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011525355A5 (enExample
JP2011525355A (ja
Inventor
プロコップ，ダーウィン，ジェイ．
イ，リャン，ファ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Texas A&M University System
Original Assignee
Texas A&M University System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Texas A&M University System filed Critical Texas A&M University System
Publication of JP2011525355A publication Critical patent/JP2011525355A/ja
Publication of JP2011525355A5 publication Critical patent/JP2011525355A5/ja
Application granted granted Critical
Publication of JP5866601B2 publication Critical patent/JP5866601B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/585—Integrins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011514618A 2008-06-18 2009-06-18 医薬組成物の製造方法 Expired - Fee Related JP5866601B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7373908P 2008-06-18 2008-06-18
US61/073,739 2008-06-18
PCT/US2009/003657 WO2009154770A2 (en) 2008-06-18 2009-06-18 Mesenchymal stem cells, compositions, and methods for treatment of cardiac tissue damage

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015119567A Division JP2015199755A (ja) 2008-06-18 2015-06-12 医薬組成物

Publications (3)

Publication Number Publication Date
JP2011525355A JP2011525355A (ja) 2011-09-22
JP2011525355A5 JP2011525355A5 (enExample) 2012-08-02
JP5866601B2 true JP5866601B2 (ja) 2016-02-17

Family

ID=41434601

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011514618A Expired - Fee Related JP5866601B2 (ja) 2008-06-18 2009-06-18 医薬組成物の製造方法
JP2015119567A Pending JP2015199755A (ja) 2008-06-18 2015-06-12 医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015119567A Pending JP2015199755A (ja) 2008-06-18 2015-06-12 医薬組成物

Country Status (4)

Country Link
US (1) US10035834B2 (enExample)
EP (2) EP2294183B1 (enExample)
JP (2) JP5866601B2 (enExample)
WO (1) WO2009154770A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9878003B2 (en) 2006-03-06 2018-01-30 The University Of Manchester Method of treating bone disorders using TSG-6
EP2485741A4 (en) * 2009-10-06 2013-07-24 Cohen Mcniece Foundation PREPARATION AND USE OF STROMAL CELLS FOR THE TREATMENT OF CARDIAC DISORDERS
CN102884177B (zh) 2010-02-18 2015-06-10 康干细胞生物技术有限公司 Cd49f通过pi3k/akt/gsk3途径促进成体干细胞的增殖、专能性和重编程
KR101869077B1 (ko) * 2010-05-03 2018-06-22 더 텍사스 에이 & 엠 유니버시티 시스템 눈 손상 및 질환 치료용 성체 줄기 세포／전구 세포 및 줄기 세포 단백질
IL282198B2 (en) 2011-09-11 2025-11-01 Minovia Therapeutics Ltd Compositions of functional mitochondria and uses thereof
EP2626369A1 (en) * 2011-11-24 2013-08-14 Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Engineered mesenchymal stem cells and their therapeutic use
RU2482182C1 (ru) * 2011-12-02 2013-05-20 Государственное научное учреждение Всероссийский научно-исследовательский институт экспериментальной ветеринарии им. Я.Р. Коваленко Российской академии сельскохозяйственных наук (ГНУ ВИЭВ Россельхозакадемии) КУЛЬТУРА МУЛЬТИПОТЕНТНЫХ МЕЗЕНХИМНЫХ СТВОЛОВЫХ КЛЕТОК, ВЫДЕЛЕННЫХ ИЗ ЖИРОВОЙ ТКАНИ КРУПНОГО РОГАТОГО СКОТА (Textus adiposus Bos taurus), ДЛЯ ВЕТЕРИНАРИИ, КЛЕТОЧНОЙ И ТКАНЕВОЙ ИНЖЕНЕРИИ
RU2482183C1 (ru) * 2011-12-02 2013-05-20 Государственное научное учреждение Всероссийский научно-исследовательский институт экспериментальной ветеринарии им. Я.Р. Коваленко Российской академии сельскохозяйственных наук (ГНУ ВИЭВ Россельхозакадемии) КУЛЬТУРА МУЛЬТИПОТЕНТНЫХ МЕЗЕНХИМНЫХ СТВОЛОВЫХ КЛЕТОК, ВЫДЕЛЕННЫХ ИЗ КОСТНОГО МОЗГА КРУПНОГО РОГАТОГО СКОТА (Medulla ossium Bos taurus), ДЛЯ ВЕТЕРИНАРИИ, КЛЕТОЧНОЙ И ТКАНЕВОЙ ИНЖЕНЕРИИ
US10702556B2 (en) 2012-05-16 2020-07-07 Minovia Therpautices Ltd. Compositions and methods for inducing angiogenesis
EP2908910A4 (en) * 2012-10-17 2016-06-29 Texas A & M Univ Sys TREATMENT OF BRAIN DAMAGE OR TRAUMA WITH TSG-6 PROTEIN
WO2016081032A2 (en) * 2014-07-11 2016-05-26 The Texas A&M University System Mesenchymal stem cells derived from induced pluripotent stem cells
WO2016018761A1 (en) * 2014-07-28 2016-02-04 The Texas A&M University System Mesenchymal stem cells expressing biomarkers that predict the effectiveness of the mesenchymal stem cells for treating diseases and disorders
US20180030413A1 (en) 2015-02-26 2018-02-01 Minovia Therapeutics Ltd. Mammalian cells enriched with functional mitochondria
KR101816246B1 (ko) * 2016-09-07 2018-01-08 에스씨엠생명과학 주식회사 염증 자극된 중간엽 줄기세포를 포함하는 면역질환 또는 염증 질환의 예방 또는 치료용 약학적 조성물
CN110352240A (zh) * 2016-12-12 2019-10-18 北京汉氏联合生物技术股份有限公司 围产期组织衍生的间充质干细胞：其制备方法和用途
US20200085881A1 (en) * 2016-12-16 2020-03-19 Osaka Air Machine Service, Ltd. Tissue healing agent
WO2018123968A1 (ja) * 2016-12-28 2018-07-05 株式会社ツーセル 生体組織損傷の修復剤および当該修復剤の製造方法
CN110423721B (zh) * 2018-05-01 2024-02-27 云南济慈再生医学研究院有限公司 一种年轻化的修复型成纤维细胞的制备方法及其应用
EP3823644A4 (en) 2018-07-22 2022-06-08 Minovia Therapeutics Ltd. MITOCHONDRIAL AUGMENTATION THERAPY OF PANCREATIC DISEASES
WO2020021539A1 (en) 2018-07-22 2020-01-30 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of muscle diseases
JP7524157B2 (ja) 2018-07-22 2024-07-29 ミノヴィア セラピューティクス リミテッド 脳疾患のミトコンドリア増強療法
US12502408B2 (en) 2018-07-22 2025-12-23 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy for primary mitochondrial diseases
US12329781B2 (en) 2018-07-22 2025-06-17 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of renal diseases
WO2020021535A1 (en) 2018-07-22 2020-01-30 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of ocular diseases
US20220348880A1 (en) * 2019-08-30 2022-11-03 The Texas A&M University System Xenogen-Free Mesenchymal Stem Cell Compositions and Methods of Use
MX2022012157A (es) 2020-03-31 2023-02-15 Minovia Therapeutics Ltd Celulas geneticamente modificadas enriquecidas con mitocondrias y usos de estas.
US20230263835A1 (en) * 2020-07-17 2023-08-24 Lg Chem, Ltd. Composition for preventing or treating osteoarthritis, comprising mesenchymal stem cell expressing tumor necrosis factor-inducible gene 6
KR20250085398A (ko) * 2023-12-05 2025-06-12 재단법인 아산사회복지재단 턱관절 질환의 예방 또는 치료용 줄기세포 치료제 및 이의 제조방법
CN121714607B (zh) * 2026-02-05 2026-06-26 杭州易文赛生物技术有限公司 一种间充质干细胞在制备治疗纤维化疾病的药物中的用途及药物组合物

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5272065A (en) 1983-10-20 1993-12-21 Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US4978745A (en) 1987-11-23 1990-12-18 Centocor, Inc. Immunoreactive heterochain antibodies
US4975369A (en) 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
US5087617A (en) 1989-02-15 1992-02-11 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
WO1992012175A1 (en) * 1991-01-14 1992-07-23 New York University Cytokine-induced protein, tsg-6, dna coding therefor and uses thereof
EP0593663A4 (en) 1991-07-03 1996-10-30 Regeneron Pharma Method and assay system for neurotrophin activity
WO1995021381A1 (en) 1994-02-01 1995-08-10 The Rockefeller University Methods and agents for measuring and controlling multidrug resistance
AU6590896A (en) * 1995-07-20 1997-02-18 New York University Pharmaceutical compositions containing tsg-6 for treating inflammatory diseases and cancer-related pathologies and methods
AU749348B2 (en) 1997-02-26 2002-06-27 General Hospital Corporation, The Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's disease
WO1999003973A1 (en) * 1997-07-14 1999-01-28 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
BR9909422A (pt) * 1998-04-02 2001-09-11 Genentech Inc Método para tratamento de hipertrofia cardìaca, método para preparação de composição farmacêutica para o tratamento de hipertrofia cardìaca e seu produto farmacêutico
US20040214836A1 (en) * 1998-05-29 2004-10-28 Cheresh David A. Method of treatment of myocardial infarction
HRP20010188A2 (en) * 1998-09-15 2002-04-30 Pharmexa As Method for down-regulating osteoprotegerin ligand activity
US6872546B1 (en) * 1998-12-23 2005-03-29 Human Genome Sciences, Inc. Hyaluronan-binding proteins and encoding genes
US6610503B1 (en) 1999-03-17 2003-08-26 Xenogen Corporation Animal models for predicting sepsis mortality
AU5062100A (en) 1999-06-14 2001-01-02 Novo Nordisk A/S Fviia/tf activity inhibiting compounds
US6632979B2 (en) 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
CA2340461A1 (en) * 2000-03-30 2001-09-30 University Of Manitoba Hirulog-like peptide and gene therapy
US6905839B2 (en) 2002-07-31 2005-06-14 Takashi Furuta In vivo phenotyping for human cytochrome P450 3A activity
US20070010008A1 (en) * 2005-06-29 2007-01-11 Tissuetech, Inc. Ex vivo expansion of primary animal cells
BRPI0414961A (pt) * 2003-10-03 2006-11-07 Keiichi Fukuda processo de indução da diferenciação de células tronco em células do miocárdio
US9002545B2 (en) 2011-01-07 2015-04-07 Wabtec Holding Corp. Data improvement system and method

Also Published As

Publication number Publication date
WO2009154770A3 (en) 2010-03-18
US20100278790A1 (en) 2010-11-04
JP2015199755A (ja) 2015-11-12
US10035834B2 (en) 2018-07-31
WO2009154770A2 (en) 2009-12-23
EP3029061A1 (en) 2016-06-08
EP2294183A2 (en) 2011-03-16
EP3029061B1 (en) 2017-09-13
EP2294183B1 (en) 2015-12-16
EP2294183A4 (en) 2012-08-15
JP2011525355A (ja) 2011-09-22

Similar Documents

Publication Publication Date Title
US10035834B2 (en) Mesenchymal stem cells, compositions, and methods for treatment of cardiac tissue damage
Lewis‐McDougall et al. Aged‐senescent cells contribute to impaired heart regeneration
Bieback et al. Mesenchymal stromal cells from umbilical cord blood
Qu-Petersen et al. Identification of a novel population of muscle stem cells in mice: potential for muscle regeneration
US20190240259A1 (en) Mesenchymal stem cells and uses therefor
AU2013290146B2 (en) Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
ES2914692T3 (es) Células madre adhesivas derivadas de cordón umbilical mejoradas, método de preparación para las mismas, y uso de las mismas
Um et al. Prospects for the therapeutic development of umbilical cord blood-derived mesenchymal stem cells
Kulisara Marupanthorn et al. The effects of TNF-α on osteogenic differentiation of umbilical cord derived mesenchymal stem cells
JP2024515690A (ja) 疾患の治療のための間葉系間質細胞からの細胞外小胞
Yew et al. Efficient expansion of mesenchymal stem cells from mouse bone marrow under hypoxic conditions
KR20130106432A (ko) 중간엽 줄기세포로 췌장염을 치료하는 방법
CN106701668B (zh) 间质干细胞、其纯株化扩张的方法及其应用
US20190224243A1 (en) Enhancement of the Beneficial Effects of Mesenchymal Stem Cell Treatment by the Caveolin-1 Scaffolding Domain Peptide and Subdomains
JP2021512654A (ja) 温熱条件の組織からの幹細胞の単離方法及びその使用
CN115803436A (zh) 免疫原性降低的新型移植细胞
US20250195582A1 (en) Immune modulatory paracrine acting cells (impacs)
Szydlak Therapeutic application of perinatal stem cells in cardiovascular diseases: current Progress and future prospects
De Becker Influence of in vitro expansion conditions on biological properties of bone marrow-derived mesenchymal stromal cells
Mabotuwana The Identification of Novel Paracrine Factors Expressed by Human Stem Cells of Mesenchymal Origin to Develop Regenerative Non-Cellular Therapies for Cardiac Fibrosis
Sandhu Master of Veterinary
Zanier et al. The contribution of mesenchymal stromal cells in traumatic brain injury
Ranzoni Bone repair potential of human amniotic fluid stem cells
Packthongsuk Detection of porcine umbilical cord matrix stem cells in the intestine and other organs after oral and intraperitoneal administration to allogeneic recipients
Kujoth et al. Embryonic Stem Cell-Derived Multipotent Mesenchymal Stromal Cell Therapy Following Focal Ischemia in the Rat

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120615

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120615

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140501

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140604

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150113

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150409

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150612

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150728

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151023

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151030

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20151124

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20151202

R150 Certificate of patent or registration of utility model

Ref document number: 5866601

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees